

FEB 10 2006

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (571) 273-8300 on February 10, 2006.

AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE –  
EXAMINING GROUP 1644

TOWNSEND and TOWNSEND and CREW LLP

By: 

Pamela Skelton

PATENT

Attorney Docket No.: 015280-397100US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

ROBERTS and KRUTZSCH

Application No.: 10/030,735

Filed: January 9, 2002

For: PEPTIDES AND THEIR UTILITY  
IN MODULATION OF BEHAVIOR OF  
CELLS EXPRESSING  $\alpha 3 \beta 1$   
INTEGRINS

Customer No.: 45115

Confirmation No. 8279

Examiner: Haddad, Maher M.

Technology Center/Art Unit: 1644

AMENDMENT AND REPLY UNDER 37  
CFR § 1.116EXAMINING GROUP 1644

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is a second response to the “final” Office Action mailed July 12, 2005, which set October 12, 2005 as the initial deadline for response. A previous response and a Notice of Appeal were filed on November 11, 2005. Thus a Petition for a one-month extension of time until February 11, 2006 is enclosed herewith, and this Second Reply is believed to be timely.

This second response is also responsive to the Advisory Action mailed December 29, 2005, which indicated that the response filed November 11, 2005 “will be entered” for the purposes of appeal. In the event that an appeal will be found unnecessary, this second response repeats the previous revisions to the specification and claims except as noted below. The arguments from the response filed November 11, 2005, to the extent that they are not repeated herein, are expressly incorporated by reference as if fully set forth as needed.

Appl. No. 10/030,735  
Amdt. dated February 10, 2006  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1644

PATENT

Claims 1-5, 7-10, 13, 14, 20, 21, 23-26, 28-30, and 46-54 are pending, with claims 20, 21, 23-26, and 28-30 withdrawn from consideration, and claims 4, 10, 53 and 54 indicated as allowable. Claims 1-3, 5, 7-9, 13, 14, and 46-52 are rejected. Reconsideration in light of the following revisions and remarks is respectfully requested.

**Amendments to the Specification** begin on page 3 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 5 of this paper.

**Remarks/Arguments** begin on page 10 of this paper.